Prior authorization criteria for Opzelura (ruxolitinib) topical
Customize your policy alerts
Sign up for all West Virginia Bureau for Medical Services (Department of Human Services) policy alerts
Know when West Virginia Bureau for Medical Services (Department of Human Services) releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements and clinical criteria for coverage of topical ruxolitinib (Opzelura) for mild to moderate atopic dermatitis in patients meeting FDA age indications, for West Virginia Bureau for Medical Services members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Topical Ruxolitinib (Opzelura)
inv-01: Initial Approval Criteria
Covered when ALL of the following are met:
Initial Approval
- Diagnosis: Patient has a diagnosis of mild to moderate atopic dermatitis
- Age: Patient is within the age range as recommended by the FDA label and indication>= 12 years per FDA label
- Prescriber: Prescribed by, or in consultation with, an allergist, immunologist, or dermatologist
- BSA: Affected body surface area is < 20%< 20%
- Prior Therapy Trials: Patient has had inadequate response, intolerance, or contraindication after minimum 30-day trials of each: (a) a medium-to-high potency topical corticosteroid (required unless affected areas are sensitive such as face, skin folds, or genitals), (b) pimecrolimus or tacrolimus, (c) Eucrisa (for mild disease)30 days each
Use of pharmaceutical samples will not be considered as meeting prior therapy requirement
inv-02: Concomitant Therapy Exclusion
Opzelura will not be approved for concomitant use with systemic immunomodulatory agents. Specifically, coverage is excluded when Opzelura is prescribed in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine.
Use of Opzelura will be considered not medically necessary when required prior therapy trials are not completed or documented, when the affected body surface area is ≥ 20%, when the patient is outside the FDA age range for the product, or when Opzelura is used concurrently with prohibited therapies. The policy requires documentation of a minimum 30-day trial of each required agent (medium-to-high potency topical corticosteroid unless treating sensitive areas, pimecrolimus or tacrolimus, and Eucrisa for mild disease); pharmaceutical samples will not be accepted as meeting these prior therapy requirements.
Key Clinical Thresholds and Coding-related Values
Prior Authorization, Step Therapy, and Documentation Requirements
Prior authorization required; approval only when all criteria met
Prior authorization is required and will be granted only when all listed criteria are met: diagnosis of mild to moderate atopic dermatitis; patient is within the FDA-labeled age range; prescribed by or in consultation with an allergist, immunologist, or dermatologist; affected BSA is < 20%; required prior therapy trials are documented; and Opzelura is not prescribed concurrently with prohibited concomitant immunomodulators. Approval duration is 8 weeks.
Step therapy: required 30-day trials of specified topical agents
Documented inadequate response, intolerance, or contraindication is required after minimum 30-day trials of each listed agent before approval will be granted.
- Medium-to-high potency topical corticosteroid (required unless treating sensitive areas such as face, skin folds, or genitals) — 30-day trial
- Pimecrolimus or tacrolimus — 30-day trial
- Eucrisa for mild atopic dermatitis — 30-day trial
- Pharmaceutical samples will not be considered as meeting prior therapy requirement
Required documentation to support prior authorization
Provide documentation that supports the clinical criteria required for approval.
- Diagnosis of mild to moderate atopic dermatitis
- Patient age consistent with FDA label/indication
- Prescriber specialty (allergist, immunologist, or dermatologist) or documentation of consult
- Affected body surface area showing < 20%
- Documentation of minimum 30-day trials (and outcomes) for each required prior therapy listed
- Statement that Opzelura will not be used in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants
- Note that pharmaceutical samples are not acceptable as prior therapy evidence
Grounds for denial if criteria or documentation missing
Requests may be denied if the submission does not meet the policy's specified clinical criteria or required supporting documentation.
- Patient does not have a diagnosis of mild to moderate atopic dermatitis
- Patient is outside the FDA-labeled age range
- Prescriber is not an allergist, immunologist, or dermatologist and no consult is documented
- Affected body surface area is ≥ 20%
- Required minimum 30-day trials of each required prior therapy are not documented or incomplete
- Opzelura is prescribed in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants (e.g., azathioprine or cyclosporine)
Background on Topical Ruxolitinib (Opzelura)
Opzelura (topical ruxolitinib) is a topical JAK inhibitor indicated for the short-term, noncontinuous chronic treatment of mild to moderate atopic dermatitis in patients who meet the FDA age indications. This policy limits approval to members with an affected body surface area of < 20% and requires prior authorization; approval duration is limited to 8 weeks.
Definitions and Policy Thresholds
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.